Table 3.

Other tyrosine kinase inhibitors for the treatment of advanced HCC.

TKI	Trial	Comparison	Setting	Enrolled Patients (%)	OS	PFS	ORR/DCR *	Grade 3–4 AEs
Donafenib (Zepsun)	Phase II–III [129]	Sorafenib	First-line	- Child–Pugh stage A (97%) - HBV (90%), HCV (2%). - Extrahepatic disease and/or Macrovascular invasion (70%)	12.1 vs. 10.3 months HR 0.831; p = 0.0245	3.7 vs. 3.6 months; p = 0.0570	4.6% vs. 2.7%, p = 0.02448 30.8% vs. 28.7%; p = 0.5532 *	38% vs. 50%; p = 0.0018
Nindetanib (BIBF 1120)	Phase II [130]	Sorafenib	First-line	- Child–Pugh Stage A (99%) - Orientals (100%) - HBV (63%), HCV (14%). - Extrahepatic disease and/or Macrovascular invasion (85%)	11.9 vs. 11.4 months; HR 0.88	5.5 vs. 3.8 months; HR 1.05		68% vs. 90%

Abbreviations: Tyrosine kinase inhibitor (TKI); Progression free-Survival (PFS); Overall Survival (OS); Objective Response Rate (ORR); Disease Control Rate (DCR) *.